Harlan Laboratories, Ltd., through its Contract Research Services (CRS) business, has entered a strategic partnership with Fluofarma, a CRO specializing in high content analysis, for drug discovery and translational medicine services. Harlan CRS will use Fluofarma’s expertise in high content analysis, biomarkers quantification and high content histology, including applications to mechanistic toxicology and prediction of toxicity.   “One of our goals is to help our customers reduce the risk of dr...